We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · June 28, 2020

First-Line Pembrolizumab in Cisplatin-Ineligible Patients With Locally Advanced or Metastatic Urothelial Cancer

Journal of Clinical Oncology

 

Additional Info

Disclosure statements are available on the authors' profiles:

Journal of Clinical Oncology
Long-Term Outcomes in KEYNOTE-052: Phase II Study Investigating First-Line Pembrolizumab in Cisplatin-Ineligible Patients With Locally Advanced or Metastatic Urothelial Cancer
J. Clin. Oncol 2020 Jun 17;[EPub Ahead of Print], J Vuky, AV Balar, D Castellano, PH O'Donnell, P Grivas, J Bellmunt, T Powles, D Bajorin, NM Hahn, MJ Savage, X Fang, JL Godwin, TL Frenkl, B Homet Moreno, R de Wit, ER Plimack

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading